Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.48
-0.2%
$5.00
$3.42
$7.20
$251.84M1.751.55 million shs448,075 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$6.85
+9.6%
$5.36
$3.79
$14.60
$343.19M-0.911.50 million shs1.51 million shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.60
$0.72
$6.24
$258.25M2.27942,366 shsN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.58
+3.5%
$4.07
$2.41
$10.37
$432.53M2.341.21 million shs1.28 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.97%-1.54%-23.25%+3.46%-26.27%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.80%+19.27%+21.83%+37.97%-5.59%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%0.00%+0.25%+315.89%-26.74%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-1.46%+2.86%+19.51%+113.89%-37.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2928 of 5 stars
0.01.00.00.02.60.80.6
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.4809 of 5 stars
3.61.00.00.03.41.70.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.4973 of 5 stars
4.24.00.00.02.72.50.0
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.4387 of 5 stars
4.61.00.00.03.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.20
Buy$22.00221.17% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10170.61% Upside

Current Analyst Ratings Breakdown

Latest INZY, CADL, SLDB, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$23.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$343.29M0.73$0.60 per share7.49$7.78 per share0.58
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,859.88N/AN/A$1.41 per share4.86
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/A$3.43 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1140.7310.18N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)

Latest INZY, CADL, SLDB, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51N/AN/AN/AN/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
8/5/2025Q2 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.36N/AN/AN/AN/AN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
4.64
4.64
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
13.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million41.79 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.52 million66.95 millionOptionable

Recent News About These Companies

What is HC Wainwright's Estimate for SLDB FY2027 Earnings?
SLDB - Solid Biosciences Inc Executives - Morningstar
SLDB Solid Biosciences Inc. - Seeking Alpha
Solid Biosciences Inc. (SLDB) - Yahoo Finance
SLDB - Solid Biosciences Inc Valuation - Morningstar
Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.48 -0.01 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.51 +0.03 (+0.67%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$6.85 +0.60 (+9.60%)
Closing price 04:00 PM Eastern
Extended Trading
$6.85 0.00 (-0.01%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.58 +0.19 (+3.53%)
Closing price 04:00 PM Eastern
Extended Trading
$5.57 -0.01 (-0.18%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.